Andere Sprachen EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Aktien

A2QJRU

US30233G2093

PV3B

Realtime-Estimate Tradegate Andere Börsenplätze 13:02:30 10.06.2024			% 5 Tage	% 1. Jan.
8.458 ^EUR	-0.33%		-14.99%	-60.78%

04.06.	EYEPOINT PHARMACEUTICALS, INC. : JPMorgan Chase bekräftigt seine Kaufempfehlung	ZM
08.05.	EYEPOINT PHARMACEUTICALS, INC. : Bewertung von Baird kaufen	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference	05.06.
EyePoint Pharmaceuticals : Investor Presentation May 2024	28.05.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	16.05.
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M	08.05.
EyePoint Pharmaceuticals: Q1 Earnings Snapshot	08.05.
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments	08.05.
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
EyePoint Pharmaceuticals : PAVIA Topline Data Conference Call Presentation	06.05.
Sector Update: Health Care Stocks Gain Pre-Bell Monday	06.05.
EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint	06.05.
EyePoint Pharmaceuticals Shares Slide 32% on Duravyu Trial Missing Primary Endpoint	06.05.
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy	06.05.
EyePoint Pharmaceuticals, Inc. Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy	06.05.
EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	17.04.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	16.04.
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists	02.04.
EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	02.04.
EyePoint Pharmaceuticals : Investor Presentation March 2024	22.03.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	18.03.
EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index	18.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Aktien

A2QJRU

US30233G2093

PV3B

Andere Sprachen

Filter